Related papers: Improved Prediction of Beta-Amyloid and Tau Burden…

The incidence of Alzheimer's disease (AD) and other forms of dementia is increasing in most western countries. For a precise and early diagnosis, several examination modalities exist, among them single-photon emission computed tomography…

Increasing effort in brain image analysis has been dedicated to early diagnosis of Alzheimer's disease (AD) based on neuroimaging data. Most existing studies have been focusing on binary classification problems, e.g., distinguishing AD…

A large number of papers have introduced novel machine learning and feature extraction methods for automatic classification of AD. However, they are difficult to reproduce because key components of the validation are often not readily…

Now that disease-modifying therapies for Alzheimer disease have been approved by regulatory agencies, the early, objective, and accurate clinical diagnosis of AD based on the lowest-cost measurement modalities possible has become an…

Alzheimer's disease (AD) is the most prevalent form of dementia, and its early diagnosis is essential for slowing disease progression. Recent studies on multimodal neuroimaging fusion using MRI and PET have achieved promising results by…

Understanding the spatiotemporal dynamics of disease progression in relation to transcriptomic profiles provides key insights into complex conditions such as Alzheimer disease. To enable such investigations, STARmap PLUS technology offers…

This paper is motivated by the joint analysis of genetic, imaging, and clinical (GIC) data collected in the Alzheimer's Disease Neuroimaging Initiative (ADNI) study. We propose a regression framework based on partially functional linear…

Alzheimer's is a neurodegenerative disease that is the most common form of dementia, but there is still no definitive cure for this disease. The noninvasive X-ray Phase Contrast Tomography (XPCT) imaging technique was used to study brain…

Alzheimer's Disease (AD) is a neurodegenerative disorder characterized by amyloid-beta plaques and tau neurofibrillary tangles, which serve as key histopathological features. The identification and segmentation of these lesions are crucial…

Deep learning (DL) for predicting Alzheimer's disease (AD) has provided timely intervention in disease progression yet still demands attentive interpretability to explain how their DL models make definitive decisions. Recently,…

With the increasing incidence of neurodegenerative diseases such as Alzheimer's Disease (AD), there is a need for further research that enhances detection and monitoring of the diseases. We present MORPHADE (Morphological Autoencoders for…

Early and accurate diagnosis of Alzheimer's disease (AD) remains a critical challenge in neuroimaging-based clinical decision support systems. In this work, we propose a novel hybrid deep learning framework that integrates Topological Data…

Alzheimer's disease (AD) is a complex neurodegenerative condition that manifests at multiple levels and involves a spectrum of abnormalities ranging from the cellular to cognitive. Here, we investigate the impact of AD-related tau-pathology…

Imaging-based early diagnosis of Alzheimer Disease (AD) has become an effective approach, especially by using nuclear medicine imaging techniques such as Positron Emission Topography (PET). In various literature it has been found that PET…

Alzheimer's disease (AD) is a neurodegenerative disease that affects nearly 50 million individuals across the globe and is one of the leading causes of deaths globally. It is projected that by 2050, the number of people affected by the…

Discriminating patients with Alzheimer's disease (AD) from healthy subjects is a crucial task in the research of Alzheimer's disease. The task can be potentially achieved by linear discriminant analysis (LDA), which is one of the most…

Alzheimer's disease (AD) is a chronic neurodegenerative condition responsible for most cases of dementia and considered as one of the greatest challenges for neuroscience in this century. Early Ad signs are usually mistaken for normal…

Alzheimer's disease (AD) is a prominent, worldwide, age-related neurodegenerative disease that currently has no systemic treatment. Strong evidence suggests that permeable amyloid-beta peptide (Abeta) oligomers, astrogliosis and reactive…

Cognitive decline is highly heterogeneous across individuals, which complicates prognosis, trial design, and treatment planning. We present the Personalized Cognitive Decline Assessment Digital Twin (PCD-DT), a multimodal and…

The cerebrospinal fluid (CSF) of 19 subjects who received a clinical diagnosis of Alzheimer's disease (AD) as well as of 5 pathological controls have been collected and analysed by Raman spectroscopy (RS). We investigated whether the raw…